

Mechanistic insights into type I toxin antitoxin systems in *Helicobacter pylori*: the importance of mRNA folding in controlling toxin expression

Hélène Arnion, Dursun Nizam Korkut, Sara Masachis Gelo, Sandrine Chabas, Jérémy Reignier, Isabelle Iost and Fabien Darfeuille*

INSERM U1212, CNRS UMR5320, Univ. Bordeaux, ARNA Laboratory, 146 rue Léo Saignat, F-33076 Bordeaux, France

Received July 08, 2016; Revised December 20, 2016; Editorial Decision December 21, 2016; Accepted December 22, 2016

ABSTRACT

Type I toxin-antitoxin (TA) systems have been identified in a wide range of bacterial genomes. Here, we report the characterization of a new type I TA system present on the chromosome of the major human gastric pathogen, *Helicobacter pylori*. We show that the *aapA1* gene encodes a 30 amino acid peptide whose artificial expression in *H. pylori* induces cell death. The synthesis of this toxin is prevented by the transcription of an antitoxin RNA, named IsoA1, expressed on the opposite strand of the toxin gene. We further reveal additional layers of post-transcriptional regulation that control toxin expression: (i) transcription of the *aapA1* gene generates a full-length transcript whose folding impedes translation (ii) a 3' end processing of this message generates a shorter transcript that, after a structural rearrangement, becomes translatable (iii) but this rearrangement also leads to the formation of two stem-loop structures allowing formation of an extended duplex with IsoA1 via kissing-loop interactions. This interaction ensures both the translation inhibition of the *AapA1* active message and its rapid degradation by RNase III, thus preventing toxin synthesis under normal growth conditions. Finally, a search for homologous mRNA structures identifies similar TA systems in a large number of *Helicobacter* and *Campylobacter* genomes.

INTRODUCTION

The bacterial pathogen *Helicobacter pylori* is the etiologic agent of chronic gastritis and peptic ulcers and plays a major role in the genesis of gastric cancer (1). About half of the human population is infected by this bacterium, which is responsible for about 700 000 deaths worldwide every year

(2). To chronically survive and multiply in the human stomach, *H. pylori* has developed original strategies to modulate its gene expression in response to various stresses. Riboregulation, which has emerged as a major level of regulation in bacteria, was also proposed to play an important role in the adaptive response of *H. pylori* (3). However apart from housekeeping RNAs, transfer-messenger RNA, signal recognition particle RNA, 6S RNA and M1 RNA (RNase P), none of the enterobacterial small non-coding RNAs (sRNAs) are conserved in this bacterium. A combination of bioinformatics and genome wide RNA-seq analysis allowed us to characterize the *H. pylori* transcriptome and to reveal the existence of more than 60 new sRNAs in *H. pylori* strain 26695 (4). Regulator of polymeric G repeats (RepG) was identified as the first example of a *trans*-acting sRNA in *H. pylori*, repressing the expression of TlpB, a chemotaxis receptor (5). Although several of the RNA-seq-identified sRNAs in *H. pylori* are putative regulators, their mechanisms and functions are still unknown.

Among the sRNA with the highest level of expression in *H. pylori* strain 26695 was an intriguing family of six homologous *cis*-encoded antisense RNAs (named IsoA1 to IsoA6) that are expressed on the opposite strand of a novel class of small mRNAs (4). Using *in vitro* translation, we previously showed that each of the small mRNA of the A family expresses a short peptide (30 amino acids), designated AapA (Antisense-associated peptide family A). We also showed that the *AapA* and *IsoA* transcripts are both constitutively expressed *in vivo* during exponential growth, defining a small expression module, repeated many times at six different chromosomal loci (I–VI) (4). *In vitro* translation of *AapA1* and *AapA3* mRNAs was specifically inhibited by their cognate IsoA1 and IsoA3 antisense RNA, respectively. Due to the gene organization of these loci, it was hypothesized that these expression modules might constitute a new family of chromosomally encoded type I toxin-antitoxin (TA) systems. The TAs systems are categorized into six types based on their genetic organization and the

*To whom correspondence should be addressed. Tel: +33 557574565; Email: fabien.darfeuille@inserm.fr

nature of the antitoxin (6,7). In the type I, the toxin is down-regulated by base-pairing of the antitoxin sRNA with the stable mRNA of the toxin (8). These systems were initially discovered on plasmids, where they play a key role in their stabilization during bacterial cell division, a phenomenon also known as post-segregational killing (9). When present on the chromosome, the identification of their function is less intuitive. A few of them have been reported to play important roles in adaptive responses to stress, including phenomena such as bacterial persistence (10).

In the present study, we characterize the *aapA1*/IsoA1 locus of *H. pylori* and demonstrate that it belongs to a new family of type I TA system. By using an artificial expression system, we show that the *aapA1* gene encodes a small peptide whose expression leads to toxicity. The synthesis of the toxin is prevented by IsoA1 sRNA which thus acts as an antitoxin. Surprisingly, the use of rifampicin during RNA decay measurements reveals the existence of a transcript generated from a 3' processing of the highly stable *AapA1* full-length (FL) mRNA. By using *in vitro* translation assays and footprinting experiments, we further demonstrate that, in contrast to the FL mRNA, the processed *AapA1* mRNA can be translated due to a structural rearrangement of the 5' untranslated region (UTR). This truncated transcript binds IsoA1, creating an extended duplex that prevents ribosome binding and that is targeted for degradation by RNase III. This degradation prevents the accumulation of the active message, and, together with the particular folding of the FL mRNA allow *H. pylori* growth despite the presence of a toxic gene in its genome. Finally, we take advantage of the strong conservation of the mRNA folding properties of this new TA system to identify many homologs in other *Helicobacter* and *Campylobacter* species. Interestingly, they are not only present on the chromosome but also associated with mobile genetic elements (MGE) such as plasmids, prophages and integrative and conjugative elements (ICE).

MATERIALS AND METHODS

Molecular techniques

Molecular biology experiments were performed according to standard procedures and the supplier (NEB) recommendations. QIAprep Spin Miniprep Kit (Qiagen), PureLink® HiPure Plasmid Maxiprep Kit (Thermo Fisher Scientific) and QIAamp DNA Mini Kit (Qiagen) were used for plasmids preparations and *H. pylori* genomic DNA extractions, respectively. PCR were performed either with Taq Core DNA polymerase (MP Biomedicals), or with Phusion Hot Start DNA polymerase (Finnzymes) when the product required high fidelity polymerase.

H. pylori strains and culture conditions

The *H. pylori* strains used in this study (Supplementary Table S1) were 26 695 (11) B128 (12,13) and X47-2AL (14). Strains were grown on Columbia agar plates supplemented with 7% horse blood and Dent selective supplement (Oxoid, Basingstoke, UK) for 24–48 h depending on the strain. Liquid cultures were performed in brain-heart infusion medium (Oxoid) supplemented with 10% fetal bovine

serum and Dent. *H. pylori* plates and liquid cultures were incubated at 37°C under microaerobic conditions (10% CO₂, 6% O₂, 84% N₂) using an Anoxomat (MART microbiology) atmosphere generator. For liquid cultures, bacteria harvested from plates were inoculated at an optical density at 600 nm of 0.05 (OD₆₀₀ = 0.05) into 5 ml (tubes, shaking at 175 rpm) brain-heart infusion medium supplemented with 10% fetal bovine serum and Dent supplement. After 12–24 h, pre-cultures were diluted to an OD₆₀₀ of 0.05 into 25 ml (flasks, shaking at 125 rpm). Plasmids used for cloning were amplified in *Escherichia coli* strain JM109, which was grown in Luria–Bertani medium, supplemented either with kanamycin (50 µg.ml⁻¹) or chloramphenicol (30 µg.ml⁻¹). For *H. pylori* mutant selection and culture, antibiotics were used at the following final concentrations 20 µg.ml⁻¹ kanamycin (Sigma) and 8 µg.ml⁻¹ chloramphenicol (Sigma).

Construction of *H. pylori* mutant strains

Chromosomal mutants of *H. pylori* (Supplementary Table S1) were obtained by natural transformation as previously described (15). The $\Delta aapA1$ /IsoA1, Δrnc , *aapA1*^{Δ-10 box} mutants and X47-2AL *aapA1*²⁶⁶⁹⁵ or *aapA1*^{B128} complementation strains were constructed by homologous recombination using a PCR cassette carrying an antibiotic resistance gene (*aphA-3* or *catGC* gene conferring kanamycin or chloramphenicol resistance, respectively), flanked by approximately 500 base-pairs (bp) regions upstream and downstream of the gene of interest, as previously described (16). For the *aapA1*/IsoA1 deletion, the region between nt 1 245 653 to 1 245 866 (encompassing the Shine–Dalgarno (SD) sequence and the ATG and TAG codons) was removed, placing *aphA-3* (from its own SD to its own stop codon) under the control of the *aapA1* promoter and upstream of a transcriptional terminator (Supplementary Figure S8). The B128 and X47-2AL Δrnc strains were constructed by replacing the *rnc* Open Reading Frame (ORF) (from the ATG to 24 nt before its stop codon) by the *aphA-3* gene amplified from its own ATG to its own TAG (Supplementary Figure S11). The *aapA1*^{Δ-10 box} mutant was constructed by removing the two last nt of the *aapA1* -10 box sequence (TAAAAT) (Supplementary Figure S9). To construct the X47-2AL *aapA1*²⁶⁶⁹⁵ / *aapA1*^{B128} complementation strains, the *aapA1* locus (nt 1 245 624 to 1 245 986 for 26695 strain and 287 085 to 286 691 for B128 strain) with its own promoter (either from strain 26695 or B128) was fused to the *catGC* resistance gene and inserted into the *rdxA* locus of the X47-2AL strain. RdxA is a non-essential gene routinely used for complementation in *H. pylori* (17). The X47-2AL has a non-homologous copy of the *aapA1*/IsoA1 module (Supplementary Figure S10). The genomic DNA of *H. pylori* strain 26695, B128, P12 *repG*:*aphA-3* (5) and the vectors pUC18K2 (kanamycin resistance gene) and pILL2150 (chloramphenicol resistance gene) were used as template for all PCR amplifications (see plasmids and primers list, Supplementary Table S2 and S3, respectively).

Plasmids constructions

Three plasmids carrying different isoforms of the *aapA1*/IsoA1 locus (from the start codon to the 3' UTR) were generated for this study. The pA1-IsoA1 plasmid contains the wild-type *aapA1*/IsoA1 sequence; the pA1 plasmid carries two mutations that inactivate the *isoA1* promoter without changing the coding sequence of the peptide and pA1* is a derivative of pA1 containing an additional mutation in the start codon of AapA1 (ATG → ATT). The pA1-IsoA1 and pA1 plasmids were obtained by PCR amplification of genomic DNA from the 26695 strain, with the primer pairs FD213/FD180 and FD212/FD180, respectively. These products were cloned into pILL2157bis (18) between the *NdeI* and *BamHI* restriction sites (Supplementary Table S2). The pA1* plasmid was obtained by site-directed mutagenesis of the pA1 plasmid using primers FD608/FD609. The resulting plasmids were introduced into *H. pylori* strain B128 by mobilization, as described in Backert *et al.* (19).

Total RNA extraction

For RNA extraction, bacterial growth was stopped at the desired OD600 by adding 1.25 ml cold stop solution (95% ethanol, 5% acidic phenol) to 10 ml of culture, which was placed on ice. Cells were then centrifuged for 10 min at 3500 rpm at 4°C, and the pellets were stored at -80°C. Cell pellets were resuspended in 600 µl lysis solution (20 mM NaAc pH 5.2, 0.5% sodium dodecyl sulphate (SDS), 1 mM ethylenediaminetetraacetic acid (EDTA)) and added to 600 µl hot acidic phenol. After 6–10 min incubation at 65°C, the mixture was centrifuged for 10 min at 13 000 rpm at room temperature. Next the aqueous phase was transferred to a phase locked gel tube (Eppendorf) with an equal volume of chloroform and centrifuged 10 min at 13 000 rpm at room temperature. Total RNA was then precipitated from the aqueous phase by adding 2.5 volumes of EtOH 100% and 10% 3 M NaOAc pH 5.2. For RNA half-life determinations, rifampicin (Sigma, prepared at 34 mg.ml⁻¹ in methanol) was added to the culture at a final concentration of 80 µg.ml⁻¹ and cells were harvested after 0, 2, 5, 10, 20, 30, 60, 120 and 240 min of incubation. A culture where rifampicin was replaced by the same volume of methanol served as a non-treated control.

Northern blot

For Northern blot analysis, 5–20 µg of total RNA were separated on an 8% polyacrylamide (PAA), 7 M urea, 1X Tris Borate EDTA (TBE) gel. RNA was transferred to a nylon membrane (HybondTM-N, GE Healthcare Life Science) by electroblotting in TBE 1X at 8V overnight. Then RNA was cross-linked to the membrane by UV irradiation and hybridized with 5'-labeled (γ ³²P) oligodeoxynucleotides (see Supplementary Table S3) in a modified Church buffer (1 mM EDTA, 0.5 M NaPO₄ pH 7.2, 7% SDS) overnight at 42°C. Membranes were washed two times for 5 min in 2X SSC, 0.1% SDS and revealed using a Pharos FX phosphorimager (Biorad).

For riboprobe synthesis, a DNA template containing a T7 promoter sequence was amplified by PCR with primers

FD671/FD672 from the 26695 strain genomic DNA as template. The *AapA1* riboprobe was prepared as described in the Maxiscript Kit (Ambion) and purified on a Sephadex G50 column. Hybridization was performed in the modified Church buffer at 64°C and the membrane was washed 2 times for 5 min in 2X SSC, 0.1% SDS at 64°C.

In vitro transcription and translation assays

For *in vitro* synthesis of the *AapA* and *IsoA* RNAs, DNA templates were amplified from *H. pylori* 26695 genomic DNA using the primer pairs FD54/FD452 (*AapA1-FL*), FD54/FD55 (*AapA1-Tr1*), FD9 /FD15 (*IsoA1 wt*), FD205/FD234 (*IsoA1L1L2*), each forward primer carrying a T7 promoter sequence (see Supplementary Table S3). FD205/FD234 primers carry both three mutations resulting in the synthesis of the *IsoA1L1L2* RNA that contains three mutations in each loop. *In vitro* transcription was carried out using the MEGAscript[®] T7 Transcription Kit (Ambion #AM1334) according to the manufacturer's protocol. After phenol:chloroform extraction followed by isopropanol precipitation, the RNA samples were desalted by gel filtration using a sephadex G-50 or G-25 (GE Healthcare) column, depending on the RNA size. For *in vitro* translation of the *AapA1-FL* and *AapA1-Tr1* mRNAs, 0.05 to 1 µg of RNA was added to the *E. coli* S30 kit (Promega, #L1030) as previously described (4).

In vitro structure probing

AapA1 transcripts were first dephosphorylated by the CIP alkaline phosphatase (NEB) and then labeled with 10 pmol of γ ³²P-ATP and T4 PNK enzyme (NEB). Labeled RNA was purified on an 8% PAA containing 7 M urea 1X TBE and eluted overnight at 4°C under shaking in 750 µl elution buffer (0.1 M NaOAc pH 5.2, 0.1% SDS). Then, RNA was extracted by phenol:chloroform, desalted and concentrated by ethanol precipitation, pellets were resuspended in 50 µl H₂O and stored at -20°C. Before use, each *in vitro* transcribed RNA was denatured by incubation at 90°C for 2 min in the absence of magnesium and salt, then chilled on ice for 1 min, followed by a renaturation step at room temperature for 15 min in 1X Structure Buffer (10 mM Tris-HCl pH 7.0, 10 mM MgCl₂, 100 mM KCl).

Structures probing analyses were performed as described previously (4,20), using 0.1 pmol of labeled *AapA1 RNA*. To determine the secondary structure of RNA in native conditions (N), 1 µl RNase T1 (0.01 U.µl⁻¹; Ambion, #AM2283), 1 µl RNase TA (0.005 µg.ml⁻¹; Ambion, #AM2275) and 1 µl of RNase V1 (0.0005 U.µl⁻¹; Ambion, #AM2275) were added to the labeled RNA and incubated in 1X Structure Buffer for 1 to 2 min at 37°C. For the denaturing conditions (D), 1X Sequencing Buffer (20 mM Sodium Citrate, pH 5.0, 1 mM EDTA, 7M Urea) was used, with the same RNase T1 concentration and 1 µl of RNase TA (0.01U.µl-1) and incubation was performed at 37°C for 5 min. We performed lead acetate (5 mM final concentration) digestions on both *aapA1-Tr1* and *aapA1-FL* in the absence or in the presence of a 2- or 10-fold excess of wild-type or mutated *IsoA1* RNAs. All the reactions were stopped by adding 10 µl of 2X Loading Buffer (95% formamide, 18 mM EDTA, Xylene Blue and Bromophenol

Blue) and stored at -20°C . Cleaved fragments were then analyzed on an 8% denaturing PAA gel containing 7 M urea and 1X TBE. Gels were dried 45 min at 80°C , and revealed using a Pharos FX phosphorimager (Biorad).

Sequence conservation analysis

A sequence similarity search for *AapA* mRNA homologs was carried out on the *Helicobacter* and *Campylobacter* genomes using the Geneious program on an iterative process (Geneious version 8.1.3 <http://www.geneious.com> (21)). Genome sequences used are listed in Supplementary Table S4. A sequence similarity with a threshold of 60% was used as a first restraint with the *H. pylori* 26695 *aapA*/IsoA nucleotide (nt) sequence (see Supplementary Figure S12 for more details). Once identified, the secondary structure of the *AapA* and IsoA RNAs were analyzed via the RNA fold plugin (22) implemented in Geneious. Finally, each locus was manually inspected for the presence of a promoter for both *aapA* and IsoA RNAs, as well as the presence of a SD sequence upstream of the *AapA* ORF. Every new result was added to the query database and the process was completed when no new result was found (Supplementary Figure S13).

RESULTS

The expression of AapA1 peptide is toxic to *H. pylori*

In the present study, our first goal was to establish whether the *aapA1*/IsoA1 module located at the locus I of the *H. pylori* strain 26695 encodes a type I TA system (Figure 1). Indeed, we previously reported that *in vitro* translation of the *AapA1* mRNA leads to the synthesis of a small peptide of 30 amino acids whose expression is repressed *in vitro* by a small antisense RNA named IsoA1 (4). To this end, we cloned the coding sequence of this peptide into an *E. coli*/*H. pylori* shuttle vector (18) under the control of an isopropyl- β -D-thiogalactopyranoside (IPTG)-inducible promoter to generate plasmid pA1-IsoA1 (Figure 2A). Two mutated variants of this plasmid were also constructed. The first one carries two mutations in the IsoA1 antisense promoter (TATAAT \rightarrow TACAAG) that prevents the expression of the antisense RNA without changing the peptide sequence (pA1 plasmid). The second one contains an additional mutation in the *AapA1* mRNA start codon (ATG \rightarrow ATT), which prevents the expression of the AapA1 peptide (plasmid pA1*) (Figure 2A). Each plasmid was transformed into *H. pylori* B128 strain deleted for the chromosomal copy of *aapA1*/IsoA1. The transcripts expressed from the different constructs were analyzed by Northern blot (Supplementary Figure S1A). We confirmed the inducible expression of the *AapA1* transcripts in presence of IPTG despite some leakiness of the promoter in absence of IPTG. We also showed that the mutated *isoA1* promoter is inactive, as shown by the absence of IsoA1 (Supplementary Figure S1A).

We next analyzed the effects of the AapA1 peptide expression on both growth rate (Figure 2B) and cell viability (Figure 2C). In the strain carrying plasmid pA1, induction of AapA1 expression caused an immediate growth arrest and a 10^4 -fold decrease in cell number (Figure 2B and C). When IPTG was washed out from the cultures after 8

h of induction, cells expressing AapA1 were not able to recover growth (data not shown). Thus, expression of AapA1 is strongly toxic and bactericidal, and the onset of toxicity is fast relative to the generation time (3.8 h for pA1 expressing strain compared to 3.6 h for pA1-IsoA1 and pA1*). Of note, no cell lysis was observed upon expression of the toxin (Figure 2B). Interestingly, this lethality was correlated with a dramatic degradation of the 23S and 16S ribosomal RNAs while the toxin-encoding mRNA was still present (Figure 2D and Supplementary Figure S1B). The toxicity was not observed in the strain carrying the pA1-IsoA1 plasmid, demonstrating that transcription of IsoA1 prevents the toxicity of AapA1 and thus indeed acts as an RNA antitoxin. In addition, the absence of toxicity of the pA1* plasmid (in which the translation of the *AapA1* mRNA is abolished) demonstrates that the toxicity is specifically due to the AapA1 peptide expression and not to the AapA1-encoding mRNA. The same results were obtained when using the wild-type background instead of the Δ *aapA1* B128 strain, indicating that the chromosomal copy of IsoA1 cannot neutralize the ectopic expression of AapA1 (Supplementary Figure S1B).

Altogether these experiments demonstrate that the *aapA1*/IsoA1 module functions like a type I TA system in which the expression of a toxic peptide is prevented by the expression of an RNA antitoxin.

3'-processing of *AapA1* mRNA triggers translation activation

Type I TA systems are often characterized by a differential stability between the toxin-encoding mRNA and the antitoxin. To analyze the stability of both *AapA1* and *IsoA1* transcripts, cultures of *H. pylori* 26695 strain were treated with rifampicin to block transcription, and total RNA was extracted at different time points and analyzed by Northern Blot (Figure 3A). An oligonucleotide probe (FD47) targeting the *AapA1* coding region detected several species from 175 to 250 nucleotides (nt) (Figure 3A, left panel). A similar pattern of expression was confirmed with a ribo-probe directed against the first 225 nt of the mRNA (Supplementary Figure S2). None of these transcripts were detected in a strain deleted for the *aapA1* promoter (Figure 3A right panel) showing that they are all produced from the same transcription start site at the position 1245705 (4). The strongest signal corresponds to the FL transcript of 250 nt (designated AapA1_FL), which displays a very slow decay with a half-life longer than 3 h. In contrast, the IsoA1 RNA has a relative short half-life of 15 min (Figure 3B). Most interestingly, 120 min after rifampicin addition, a transcript of around 225 nt appears. Since transcription is blocked, this transcript is the result of *AapA1*_FL processing and was consequently designated as *AapA1*_Tr1 (for truncated) (Figure 3A). Different probes targeting either the 5' or 3' end of the *aapA1*_FL revealed that the truncation occurs around 25 nt upstream of the 3' end of the FL message (Supplementary Figure S3). Another transcript of 172 nt, named *AapA1*_Tr2 was detected with FD47 but not with FA115 and FA116 probes (corresponding to the 5' and 3' ends of *AapA1*) indicating that this transcript is the result of cleavages of the FL message at both ends. Another faint band corresponding to a transcript of \sim 200 nt was detected. However, since




Figure 1. Genetic organization of the *aapA1*/IsoA1 locus in the *H. pylori* 26695 strain. (A) Localization of the six different loci (I–VI) containing a homolog of the IsoA sRNA on the chromosome of *H. pylori* 26695 strain. The locus I containing the AapA1/IsoA1 module is shown in red. All loci are in the same orientation on the chromosome, the *aapA* gene being always on the positive strand (forward). (B) Genomic organization of the locus I. The open reading frame encoding the 30 amino acids peptide AapA1 (in black) and IsoA1 small RNA (in red) are transcribed from the intergenic region between the *deoD* gene (HP1178, purine nucleotide phosphorylase) and the *omp27* gene (HP1177, outer membrane protein). Arrows indicate the respective transcriptional start sites of each transcript and black and red bars their approximate length determined by RNA-seq analysis (4). (C) The sequence of the intergenic region containing the *aapA1*/IsoA1 module in 26695 *H. pylori* strain is shown. The AapA1 fragment cloned into the pILL2157 vector is shown in italic. Promoter sequences (boxes) of *aapA1* and *isoA1* genes are shown in black and red, respectively. The Shine–Dalgarno sequence (SD), the start and stop codons are indicated by bold letters.

it was not observed in other *H. pylori* strains tested with the riboprobe (Supplementary Figure S2), we did not explore it in the present study. During the course of the rifampicin experiment we observed that *AapA1*_*Tr1* appears at the same time that IsoA1 disappears. Since *AapA1* mRNA expression leads to toxicity when the antitoxin is absent (Figure 2), we propose that *AapA1*_*Tr1* is the active message. To test this hypothesis, the translatability of *AapA1*_*FL* and *AapA1*_*Tr1* transcripts was assessed by *in vitro* translation assays (Figure 3C). Whereas a very faint signal corresponding to AapA1 peptide was observed with the FL transcript, a strong signal was detected with the *Tr1* species (Figure 3C and 3D). These results demonstrate that a 3'-end processing is required for a fully efficient *in vitro* translation of the AapA1 peptide.

The SD sequence is accessible in the truncated mRNA and sequestered in the full-length transcript

To investigate the reasons for the differential translation efficiency of the two *AapA1* transcripts (FL and *Tr1*), we performed *in vitro* structure probing by combining chemical and enzymatic footprinting (Figure 4). RNAstructure software 5.2 (22) was used to generate secondary structure predictions of both transcripts according to the experimental data obtained (see the structures Figure 5). Lead cleavage showed a strong structural rearrangement of the 5' UTR between the two transcripts. Indeed while the cleavage pattern of *AapA1*_*FL* (Figure 4A, lane 7) fits very well with the formation of two internal loops (IL I and IL II, Figure 5), this region folds as two apical loops (AL I and AL II, Figure 5) connected by a 14 nt linker in *AapA1*_*Tr1* (Figure 4B, lane 7). *AapA1*_*FL* folding involves a long distance interaction between the 5' and 3' ends of the transcript where the SD sequence is sequestered (Figure 5). This structure predic-




Figure 2. Expression of the AapA1 peptide in *H. pylori* induces cell growth arrest, loss of viability and ribosomal RNA degradation. (A) Schematic representation of the *aapA1* gene cloned into the pILL2157-bis plasmid (Supplementary Table S2). The fragment encompassing the region from the start codon to the 3' untranslated end of the *aapA1* gene (202 nucleotides, the precise coordinates of the genomic DNA cloned in the vector are indicated, see the sequence in Figure 1C) was cloned downstream a *ureI*-derived promoter and two LacI repressor sequences (black boxes) (18). Thus the transcription of this construct leads to the production of a recombinant form of AapA1 mRNA and of an IsoA1 RNA that only shares 30 nucleotides with the original sequence and was therefore renamed IsoA1-rec (see expression in Supplementary Figure S1). The pA1 vector carries the same module except that two point mutations have been introduced to inactivate the *isoA1* promoter without changing the AapA1 amino acids sequence. In pA1*, both the *isoA1* promoter and the AapA1 start codon are mutated. Each vector has been introduced into *H. pylori* B128 strain deleted for the endogenous *aapA1*/IsoA1 module (B) Growth curves of the strains carrying either pA1, pA1* or pA1-IsoA1 vectors, in presence (black) or absence (white) of IPTG. IPTG was added at 16 h of culture. Data shown are the mean values \pm standard deviations of three biological replicates. (C) Cell viability of the strains collected at 0 or 8 h after IPTG addition. Serial dilutions of the culture were plated on CAB-chloramphenicol agar plates. (D) Expression of AapA1 in B128 $\Delta aapA1$ /IsoA1 strain results in the degradation of rRNA. Ethidium-bromide 1% agarose gel was used to analyze rRNA (RNA samples were extracted after 8 h induction as shown in B and C). One microgram of total RNA was loaded in each lane. The positions of 23S, 16S and 5S rRNAs are indicated.

tion explains the high stability of the transcript (few single stranded nucleotides accessible to RNases) but also why it is poorly translated. On the contrary, the 3'-end truncation of *AapA1_FL* leads to an important structural rearrangement in the 5' UTR in which the SD sequence becomes accessible to ribosomes (Figure 5). In addition we also observed increased lead cleavages in the residues 66–75 in Tr1 versus the FL transcript, indicating that the second stem-loop might be more accessible to ribosomes in the truncated transcript than in the full length mRNA.

This structural analysis provides the basis for the much higher translation efficiency observed with the truncated form of the AapA1 transcript as compared to the full-length message.

The truncated *AapA1* mRNA and IsoA1 RNAs interact via loop-loop interactions to form a full duplex

To characterize the interaction between *AapA1-Tr1* and *IsoA1* RNA, we performed lead probing on 5'-end-labeled *AapA1-Tr1* transcript in absence or presence of *IsoA1* RNA (Figure 4B, lanes 7, 8 and 10). A comparison of the cleavage patterns showed that a 2-fold excess of IsoA1 resulted in a complete protection of the mRNA region that is complementary to IsoA1 (Figure 4B, lane 8). Indeed, lead cleavage was strongly reduced in the 5' UTR encompassing AL I, the 14 nt linker and AL II and this was even more pronounced when IsoA1 was added in a 10-fold excess (Figure 4B, lane 10). Moreover, other structural rearrangements (highlighted with a star) were observed indicating a re-folding of the *AapA1-Tr1* transcript upon the formation of an extended duplex with IsoA1 (Figure 4B). Under the




Figure 3. A truncated *AapA1* mRNA species revealed by rifampicin treatment is efficiently translated *in vitro* (A) *AapA1* and IsoA1 transcripts half-lives were determined in the 26695 *H. pylori* strain (left panel) or in an isogenic mutant deleted for *aapA1* promoter (Δ -10 box, right panel). After rifampicin addition (at OD₆₀₀ = 1.7), aliquots of cultures were collected at several time points (as indicated on top of the gel), RNA extracted and subjected to Northern blot analysis. The same membrane was successively probed with FD47 and FD198 labeled oligonucleotides to detect either *AapA1* or IsoA1 transcripts, respectively. Arrows indicate the different transcripts: *AapA1_FL* (one star), *AapA1_Tr1* (two stars), *AapA1_Tr2* (three stars) and IsoA1 full-length and processed transcripts. A labeled DNA marker (lane M) was used for size estimation. Proper loading was assessed by staining the membrane with methylene blue (level of 5S rRNA is shown). The Northern blot shown here is a representative of more than three independent experiments using several biological replicates. (B) RNA decay was determined by plotting normalized intensities (RNA signal relative to time 0) of band corresponding to *AapA1_FL** and IsoA1 transcripts, either in the wild-type or Δ -10 box mutated strains, as function of time after rifampicin addition. Approximate half-lives (*t*_{1/2}, in min) are indicated for each transcript analyzed. (C) *In vitro* translations assays of *AapA1_FL* (left) and *AapA1_Tr1* (right). Increasing amounts of *in vitro* synthesized mRNAs (μ g) were added to *E. coli* S30 extracts in presence of ³⁵S methionine. Control lane (Ctrl) shows the translation background obtained without exogenous mRNA. Here is a representative experiment out of several independent assays. (D) The amount of AapA1 peptide produced from both transcripts (*AapA1_FL* and *Tr1*) was quantified and the intensity of the band at the highest *AapA1_Tr1* quantity (1 μ g) was set to 100%. Data are the average and standard deviations of three independent experiments.

same conditions, no interaction could be detected between *AapA1_FL* and IsoA1 (Figure 4A, lanes 8 and 10), indicating that the antisense RNA specifically targets the 3' end-processed mRNA. Additionally, structure mapping and secondary structure predictions performed on IsoA1 RNA (Supplementary Figure S4) showed that the *AapA1_Tr1* 5' UTR and IsoA1 both fold into two complementary stem-loops that could favor the formation of loop-loop interactions.

To determine whether such kissing-loop complexes could represent the initial step of the *AapA1*/IsoA1 hybrid formation, we performed *in vitro* footprinting experiments in presence of neomycin. This antibiotic of the aminoglycoside family is known to stabilize kissing complexes and to prevent the formation of extended duplexes (23). In presence of increasing concentration of neomycin, the LK region of *AapA1_Tr1* was no longer base-paired whereas the ALI and ALII loops were still protected (Supplementary Figure S5A), confirming that loop-loop interactions are promoting the interaction between the two transcripts. In addition, we could map neomycin's binding regions at the boundaries of the helices (Supplementary Figure S5A, lanes 6 and 7), explaining why this antibiotic prevents the *AapA1_Tr1*/IsoA1 hybrid to extend into a full duplex (Supplementary Figure S5A lanes 10–11). No interaction was observed with IsoA3 which displays a similar fold than IsoA1 but a different sequence in the loop (Supplementary Figure S4B).

To further confirm that the initial interaction is mediated via loop-loop interaction, we constructed an IsoA1 variant mutated in its two apical loops L1 and L2 (named IsoA1 L1L2) and tested its ability to bind the *AapA1_Tr1* transcript (Figure 4 and Supplementary Figure S6). We first verified that the three nt mutations introduced in each loop of IsoA1 did not alter its folding (Supplementary Figure S6). In contrast to the wild-type (wt) IsoA1, the addition of IsoA1 L1L2 did not change the digestion profile of *AapA1_Tr1* (Figure 4B, lanes 9 and 11) indicating that this mutant cannot bind despite a strong sequence complementarity. This result confirms that the interaction between *AapA1_Tr1* and IsoA1 is mediated via a loop-loop interaction. Finally, we performed the reverse experiment, i.e. lead cleavage of 5' end-labeled IsoA1 upon *AapA1_Tr1* addition. The results confirmed the duplex formation between IsoA1 and the first 76 nt of *AapA1_Tr1* mRNA (Supplementary Figure S6A). This very long hybrid is masking the ribosome binding site (RBS) of *AapA1_Tr1* (Supplementary Figure S5B) suggesting that the primary role of the antitoxin is to inhibit the translation of the toxin.

Taken together these data indicate that IsoA1 antisense RNA binds specifically to the *AapA1_Tr1* active transcript via kissing-loop interactions (Supplementary Figure S5B). These short interactions are key determinants in the specificity of the interaction and explain why each IsoA RNA only represses the translation of its cognate mRNA, as shown previously (4).




Figure 4. Structure probing of (A) *AapA1-FL* and (B) *AapA1-Tr1* RNAs in presence or absence of IsoA1. The secondary structure of each *in vitro* transcribed RNA was probed by submitting ~ 0.1 pmol ^{32}P -labeled RNA to partial enzymatic digestion either under native (N) or denaturing conditions (D) (RNase T1 cleaving single stranded G residues, lanes 3 and 4; RNase TA cleaving single stranded A residues, lanes 5 and 6). The interaction between *AapA1* and IsoA1 was mapped using lead probing (lanes 7–11) in the absence (lane 7) or presence of either 2 or 10 times excess of wild-type IsoA1 (wt, lanes 8 and 10) or IsoA1 mutated in its apical loop (L1L2, lanes 9 and 11). Structure mapping, as well as secondary structures of IsoA1 wt and L1L2, are shown in Supplementary Figure S4. Untreated RNA (lane 1, denoted C) and partially alkali digested RNA (lane 2, denoted OH) served as control and ladder, respectively. Cleaved fragments were analyzed on an 8% denaturing polyacrylamide gel. Positions of all G residues are indicated relative to the transcription start site of the *aapA1* gene (left of the gel). Single stranded regions involved in the 5' structural rearrangement are indicated by vertical black bars (right of the gel). The internal loops I and II (IL I, IL II) present in *AapA1-FL* are replaced by an apical loop (AL II) and a 14-nucleotides linker (LK) in *AapA1-Tr1*. Black stars on the right of the gel indicate other structural rearrangements observed following IsoA1 RNA binding.

RNase III cleavage ensures rapid turnover of the translationally active message

Base-pairing between *AapA1-Tr1* and IsoA1 creates a long duplex of 76 bp (Supplementary Figure S5B), which could be a good substrate for the double-stranded specific ribonuclease RNase III. To investigate the role of this ribonuclease in *aapA1*/IsoA1 regulation *in vivo*, we compared both transcripts in wt and RNase III-deficient *H. pylori* strains. Since we could not delete the *rnc* (HP0662) gene encoding RNase III in the 26695 strain, we used two other strains, B128 and X47-2AL, for which the deletion of *rnc* could be obtained. We inserted the complete *aapA1*/IsoA1 module of either the 26695 or the B128 strain into the *rdxA*

gene of the wt and Δrnc X47-2AL strains (see Supplementary Figure S10 for details). We then analyzed the expression of *AapA1* and IsoA1 RNAs by Northern blot (Figure 6). The introduction of either *aapA1*/IsoA1 module in the X47-2AL background resulted in the expression pattern observed for the parental strain (Figure 6, compare lanes 2 and 3 with lanes 7 and 8). Thus, transcription of the *aapA1*/IsoA1 module is not influenced by the recipient strain under these conditions. In both the X47-2AL and B128 backgrounds, the *rnc* deletion led to a strong accumulation of the *AapA1-Tr1* truncated form (two stars) while the levels of *AapA1-FL* (one star) were unaffected (Figure 6, lanes 5, 6 and 9). Same samples were run longer for a better separation of the different species (Supplementary Fig-




Figure 6. RNase III prevents accumulation of the active *AapA1_Tr1* mRNA. Expression of *AapA1* and *IsoA1* RNAs in wild type and isogenic Δrnc *H. pylori* strains (X47-2AL, 26695 and B128) were analyzed by Northern blot. The *aapA1*/*IsoA1* locus of the 26695 strain (*AapA1*²⁶⁶⁹⁵) or of the B128 strain (*AapA1*^{B128}) was inserted in the X47-2AL strain and its Δrnc derivative. Samples from each strain were collected when culture reached OD₆₀₀ ≈ 1. tRNA Val (t34) served as a loading control and was probed with the FD499 radiolabeled oligonucleotide. Upper panel: *AapA1* transcripts revealed with FD47 probe; middle panel: *IsoA1* transcripts revealed with FD198 probe.

alternative degradation of *AapA1_Tr1* mRNA by unknown ribonucleases.

Overall these data indicate that RNase III is the major enzyme responsible for the *AapA1_Tr1*/*IsoA1* duplex degradation thereby ensuring the rapid turnover of the *AapA1* active message.

Identification of new *aapA*/*IsoA* systems in other *Helicobacter* and *Campylobacter* species through structural conservation

We analyzed the conservation of the newly characterized type I *aapA*/*IsoA* TA system among the *H. pylori* strains. A PSI-BLAST search to detect small peptides (as described in (24)) resulted in very few positive hits because few ORFs encoding small proteins have been annotated. We next conducted a TBLASTN search against nucleotide database. This search revealed the presence of *aapA*/*IsoA* homologs in almost every *H. pylori* genome and in the closely related genomes of *Helicobacter acinonychis* and *Helicobacter cetorum* (Supplementary Table S4). Moreover, the synteny associated with the different loci was strongly conserved between the various strains (Supplementary Figure S12). The *aapA*/*IsoA* loci were thus classified according to their position at the 5 loci named I, III, IV, V and VI (Figure 7A). Although *IsoA2* at locus II is conserved, no functional promoter upstream of a putative *AapA2* mRNA nor a conserved small ORF longer than four amino acids were detected. Thus, this locus seems not functional and therefore was no longer considered in this study. Among the 66 *H. py-*




Figure 7. Conservation of *aapA*/*isoA* TA systems in 66 *Helicobacter pylori* strains. (A) Each genome is stacked according to the decreasing number of systems present at each locus and aligned to the origin of replication (next to the *dnaA* gene). Each locus containing at least one copy of a functional *aapA*/*IsoA* module (presence of both promoters and of a small peptide with the consensus length of 30 amino acids) is represented according to the following color code: locus I (red), III (light green), IV (dark green), V (blue) and VI (purple). Most systems have the mRNA on the positive strand; the few ones on the minus strand are shown as open dots. A thick orange line shows the presence of an integrative and conjugative element (ICE) next to an *aapA*/*isoA* module. (B) Schematic representation of the locus III alignment in *H. pylori* strains 26695, J99 and Gambia94/24. Blue and green colored genes represent the 5' and 3' side of the locus III, respectively. The *aapA* gene is in red. All the ORF contained in the ICE *Hptfs3* are shown in orange. Left (LJ) and right (RJ) junctions of the ICE are indicated.

lori complete genomes analyzed, the *aapA*/IsoA modules were present in one or multiple copies at the 5 conserved loci in all but 6 genomes that are free of intact *aapA*/IsoA systems (Figure 7A and Supplementary Table S4). We then hypothesized that, given the importance of mRNA folding in the control of the AapA1 toxin expression, this folding should be conserved. We thus carried out a search for structural mRNA homologs against all available *Helicobacter* complete genomes and other closely related species such as *Campylobacter* (Supplementary Figure S13). This search identified many new loci that were all manually inspected for features such as mRNA folding, presence of a conserved SD sequence, start and stop codons, as well as a promoter for the antisense RNA (Supplementary Figure S13). This manual inspection allowed us to dismiss a considerable fraction of detected loci. Each new positive locus was implemented for the next search in an iterative manner (see the detail of this search in Supplementary Figure S13). Interestingly, this new search identified many *AapA* mRNA homologs in other *Helicobacter* species that were not found with the TBLASTN or PSI-BLAST searches. Since the synteny was not conserved in these *Helicobacter* species, these systems were named *aapA*/IsoA without any specific number associated (Supplementary Table S4). Surprisingly, this search revealed the presence of this system near prophage encoding genes in *H. felis* ATC 49179 and *H. bizzozeronii* CIII-1 or near a transposon in *H. cetorum* MIT-99 5656 (Supplementary Figure S14). A closer look at the *H. pylori* loci revealed that some of them were associated with another type of MGE such as the ICE recently characterized in *H. pylori* genomes (25,26). For instance in Gambia94/24, a complete ICE of 46 kb named ICEHptfs3 was present in the intergenic region corresponding to the locus III, creating a much larger genomic region (Figure 7B). Finally, although no *aapA*/IsoA system was detected in *Helicobacter* plasmids, one was identified on a *Campylobacter jejuni* plasmid as well on the chromosome of some *C. jejuni* strains in a region involved in plasmid stabilization (Supplementary Figure S15).

Altogether these results indicate that while these TA systems have been discovered initially on the chromosome of *H. pylori*, their localization near MGEs such as ICE, transposon and prophage suggests that they might have been acquired via horizontal gene transfer and played a role in stabilizing these mobile elements.

DISCUSSION

In this article we characterize for the first time a type I toxin-antitoxin system in *H. pylori*. We have shown that the *aapA1* gene encodes a small peptide whose expression is toxic to *H. pylori* and found that several layers of post-transcriptional regulation are preventing the expression of this toxin, as described in our working model in Figure 8. The transcription of the *aapA1* gene generates a full-length mRNA of 250 nt, denoted *AapA1_FL* that is translationally inactive. This inert form is constitutively processed at its 3' end to generate a truncated transcript of 225 nt which is translatable. This active form denoted *AapA1_Tr1*, base pairs with the IsoA1 antisense RNA to form an extended duplex that is rapidly degraded by RNase III to generate




Figure 8. Model of the *aapA1*/IsoA1 TA system regulation. This model is based on all experimental data presented and is described in the text (see discussion). Simplified structures of *AapA1* transcripts (FL, Tr1 and Tr2) are based on Figure 5. The region encoding the AapA1 ORF in the transcript is shown with a thick black line. The Shine-Dalgarno sequence is indicated as SD. The translationally active and inactive states of the different mRNA species are also indicated.

AapA1_Tr2. In absence of IsoA1, the synthesis of AapA1 toxin can occur leading to a growth arrest and cell death.

Metastable structures prevent premature toxin expression during mRNA synthesis

While most TA systems including type II, III, IV and V, have adopted a specific operon organization allowing the production of the antitoxin before that of the toxin, type I TA systems are using an alternative strategy to prevent toxin production. Most type I toxin encoding mRNAs have their SD sequence sequestered in a stable double-stranded region that prevents expression of the toxin while the RNA is transcribed (20,27–31). In some cases, this sequestration involves a long distance base-pairing between the 5'- and 3'-UTRs (31,32). However due to transcription-translation coupling that occurs in bacteria, the RBS could be, in principle, available before the 3' region is synthesized. This particular mode of regulation implies that metastable structures sequestering the RBS are formed during transcription in order to prevent translation initiation on the nascent mRNA (31,32). To predict such transient secondary structures that are formed during transcription, we used the Kinfold stochastic simulations that predict cotranscriptional folding paths of functional RNAs (33). This simulation showed that three successive structures masking the RBS can potentially form at various stages of mRNA transcription (Supplementary Figure S16 and Video SM1 for *AapA1_FL* mRNA, data not shown for the other loci). A more stable structure replaces the first two metastable struc-

tures when transcription reaches the end of the message. Besides sequestration of the RBS, the 5' to 3' end-pairing of the full-length mRNA forms an 11 bp helix including 6 GC pairs (Figure 5) that induces an efficient transcription termination at this position. Another putative terminator stem-loop was previously annotated at the position +225 (4) but our work shows that it is not able to induce transcription termination very efficiently. In addition, the IsoA1 could, in principle, bind to the nascent AapA1 mRNA, before the RNA polymerase reaches the end of the message. This interaction could then promote the production of the Tr1 transcript. However, we believe this scenario quite unlikely because the *AapA1-Tr1* is only visible after rifampicin treatment at late stages when IsoA1 is completely degraded. In addition we would never observed accumulation of the full length mRNA. Altogether our results clearly indicate that IsoA1 is required for the degradation of Tr1 but not for its production.

AapA1 mRNA requires a 3' end processing to be translated

For type I toxin mRNAs having their SD sequence sequestered, the mechanism by which the toxin mRNA gains activation is still poorly documented. Our results show that for *AapA1*, a 3' end-processing event is required to refold the mRNA and to unmask the SD (Figure 5). Until now, two examples of type I TA systems for which the toxin is produced after the cleavage of the mRNA have been described (either in 5' for TisB or 3' end for Hok (20,34)). In contrast to the 3' end processing involved in the maturation of the *Hok* mRNA, the 3' to 5' exonucleolytic activity of the polynucleotide phosphorylase and of the ribonuclease II is not sufficient to process the 3' end of the *AapA1-FL* mRNA (H. Arnion, unpublished results). As for TisB (20), the enzymatic activity responsible for the processing remains to be identified.

IsoA1 inhibits toxin expression primarily at the translational level

In order to avoid toxin expression, IsoA1 is constitutively synthesized in a large excess over *AapA1-Tr1*. The double stem-loop structure in the 5'UTR of *AapA1-Tr1* mRNA mediates a specific recognition by the IsoA1 RNA via loop-loop interactions. *In vitro* this hybrid is then extended into a full duplex that is cleaved by the double-stranded specific RNase III. *In vivo* this degradation is very rapid since the *AapA1-Tr1* does not accumulate. However, RNase III is not essential in the B128 strain despite the presence of several *aapA*/IsoA systems in its genome, suggesting that, at least in this strain, RNase III cleavage is not mandatory for the repression of the toxin. The binding of IsoA1 to *AapA1-Tr1* is completely masking the RBS and in absence of RNase III, the stability of the long duplex formed (76 bp) is probably sufficient to prevent ribosome binding. Thus, the repression of AapA1 toxin expression by IsoA1 RNA may primarily occur at the translational level, as previously shown for other type I toxins (i.e. Hok (35), TisB (20), Fst (29) and BsrG (28)). In contrast, in *B. subtilis*, the degradation of the TxpA and YonT toxin mRNAs by RNase III is essential to prevent toxin synthesis (27,36).

Analogy with other type I TA systems

This new system identified in *epsilon* proteobacter species shares many similarities with other type I TA previously identified in enterobacteria. For instance the *aapA1*/IsoA1 system share common features with the overlapping *cis*-encoded antisense RNA regulating TA systems characterized in *E. coli* (37). Similar to *hok*/Sok and *ldr*/Rdl TA systems, this system encodes a small toxic protein (size < 50 aa) that is synthesized from a highly stable mRNA and which production is repressed by a small unstable antisense RNA. In addition, as for *hok*/Sok, the *aapA1*/IsoA1 requires a 3' processing to get activated (34). However, in contrast to these two TA systems, its translation activation does not seem to require the translation of an overlapping small ORF (like the mok and ldrX peptides of the *hok*/Sok and *ldr*/Rdl systems, respectively) (38,39). Another major difference with other TA systems relies on the fact that the IsoA1 antitoxin is directly targeting the translation initiation region of the toxin gene. This specificity is due to the genomic organization of this TA system, where the antitoxin is fully complementary to the 5' UTR of the toxin-encoding mRNA, as also shown for the *symE*/SymR TA system in *E. coli* (40).

Conservation of *aapA*/IsoA TA systems in *Helicobacter* and *Campylobacter*

Few reports have highlighted the difficulties in predicting the presence of type I TA system in bacterial genomes (24,41). Indeed the large diversity of toxin sequences as well as their small nucleotide size complicates the finding of new type I TA systems. In this report we present a new strategy taking advantage of the specific folding adopted by the AapA mRNA to identify more representatives of these systems. Our search revealed the presence of a large number of these systems in *Helicobacter* genomes, larger than anticipated (4). With the exception of a few strains that only have ghost copies of *aapA*/IsoA (i.e. with either no functional promoter and/or no SD and/or no ORF longer than 5–6 amino acids), most *H. pylori* strains contain one or multiple copies of these systems at conserved loci on the chromosome. At a given locus, they can be present in single or multiple copies, depending on the strains. The locus IV, located close to the replication origin is the most conserved one, as it is found in all the strains analyzed. Our data show that these TA systems are sometimes inactivated by point mutations, genomic rearrangements or insertion of an IS (insertion sequence) element. This is similar to what was observed for the *hok*/Sok systems present on the chromosome of *E. coli* (41). However, we also found that in some cases, the *aapA*/IsoA systems are associated with MGE. For instance our search reveals their presence on *Campylobacter* plasmids and within genomic islands coding either for an ICE element (strains shown in bold in Figure 7A) or prophage genes (*Helicobacter felis* ATCC49179 and *Helicobacter bizzozeroni* MIT 99–5656). In these cases, these newly identified TA systems may be part of a plasmid stabilization and/or addiction system as was reported for several TA systems (42). This phenomenon, also known as post-segregational killing, was first described for *hok*/Sok system (43). If a plasmid bearing a TA module is not transmitted to

a daughter cell, the unstable antitoxin is degraded while the stable toxin acts on cellular targets and kill the plasmid-free cells. For instance type II systems have already been shown to promote the maintenance of ICE element and conjugative plasmids (44,45). Whether a similar role could be played by the *aapA*/IsoA systems remains to be explored.

CONCLUSION

To conclude, the characterization of a new TA system in *H. pylori* revealed the importance of mRNA folding in type I TA regulation. We propose that the *AapA* mRNA requires two structural RNA switches to gain activation. The first one consists of a spontaneous conformational rearrangement, in which metastable 5'-end structures are disrupted in favor of a more stable 5' end/3' end interaction. The second switch is induced after a processing event done by a yet unknown RNase, which renders the mRNA translationally active. This sophisticated mechanism may be conserved for other TA systems. Another interesting characteristic of the *aapA*/IsoA system, is the high stability of the mRNA versus the instability of the antitoxin that makes it a particularly efficient addiction module. Indeed, the cell should not be able to get rid of such TA system unless a non-sense mutation is present in the toxin gene. Finally our bioinformatic analysis revealed that the *aapA*/IsoA system belongs to a novel large family of type I TA system that is not only present on the chromosome but also associated with MGEs. Although our data provide some hints for a role in stabilizing MGEs, these systems might have diverse functions depending on their genetic localization or on the organisms that host them.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENT

The authors thank Denis Dupuy, Axel Innis and Cathy Staedel for critical reading of the manuscript and all present and past members of the ARNA laboratory for helpful discussions.

FUNDING

INSERM ; Université de Bordeaux; Agence Nationale de la Recherche (<http://www.agence-nationale-recherche.fr/>) [ANR-12-BSV5-0025-Bactox1, ANR-12-BSV6-007-asSUPYCO]; European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement [642738]. Funding for open access charge: INSERM.

Conflict of interest statement. None declared.

REFERENCES

- Cover, T.L. and Blaser, M.J. (2009) *Helicobacter pylori* in health and disease. *Gastroenterology*, **136**, 1863–1873.
- Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int. J. Cancer*, **127**, 2893–2917.
- Pernitzsch, S.R. and Sharma, C.M. (2012) Transcriptome complexity and riboregulation in the human pathogen *Helicobacter pylori*. *Front. Cell. Infect. Microbiol.*, **2**, 14.
- Sharma, C.M., Hoffmann, S., Darfeuille, F., Reignier, J., Findeiß, S., Sittka, A., Chabas, S., Reiche, K., Hackermüller, J., Reinhardt, R. *et al.* (2010) The primary transcriptome of the major human pathogen *Helicobacter pylori*. *Nature*, **464**, 250–255.
- Pernitzsch, S.R., Tirier, S.M., Beier, D. and Sharma, C.M. (2014) A variable homopolymeric G-repeat defines small RNA-mediated posttranscriptional regulation of a chemotaxis receptor in *Helicobacter pylori*. *Proc. Natl. Acad. Sci. U.S.A.*, **111**, E501–510.
- Goeders, N. and Van Melderen, L. (2014) Toxin-antitoxin systems as multilevel interaction systems. *Toxins*, **6**, 304–324.
- Wen, J. and Fozo, E.M. (2014) sRNA antitoxins: more than one way to repress a toxin. *Toxins*, **6**, 2310–2335.
- Brantl, S. and Jahn, N. (2015) sRNAs in bacterial type I and type III toxin-antitoxin systems. *FEMS Microbiol. Rev.*, **39**, 413–427.
- Gerdes, K., Gulyaev, A.P., Franch, T., Pedersen, K. and Mikkelsen, N.D. (1997) Antisense RNA-regulated programmed cell death. *Annu. Rev. Genet.*, **31**, 1–31.
- Gerdes, K. and Maisonneuve, E. (2012) Bacterial persistence and toxin-antitoxin loci. *Annu. Rev. Microbiol.*, **66**, 103–123.
- Tomb, J.F., White, O., Kerlavage, A.R., Clayton, R.A., Sutton, G.G., Fleischmann, R.D., Ketchum, K.A., Klenk, H.P., Gill, S., Dougherty, B.A. *et al.* (1997) The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature*, **388**, 539–547.
- Farnbacher, M., Jahns, T., Willrodt, D., Daniel, R., Haas, R., Goemann, A., Kurtz, S. and Rieder, G. (2010) Sequencing, annotation, and comparative genome analysis of the gerbil-adapted *Helicobacter pylori* strain B8. *BMC Genomics*, **11**, 335.
- McClain, M.S., Shaffer, C.L., Israel, D.A., Peek, R.M. and Cover, T.L. (2009) Genome sequence analysis of *Helicobacter pylori* strains associated with gastric ulceration and gastric cancer. *BMC Genomics*, **10**, 3.
- Ermak, T.H., Giannasca, P.J., Nichols, R., Myers, G.A., Nedrud, J., Weltzin, R., Lee, C.K., Kleantous, H. and Monath, T.P. (1998) Immunization of mice with urease vaccine affords protection against *Helicobacter pylori* infection in the absence of antibodies and is mediated by MHC class II-restricted responses. *J. Exp. Med.*, **188**, 2277–2288.
- Skouloubris, S., Thiberge, J.M., Labigne, A. and De Reuse, H. (1998) The *Helicobacter pylori* Urel protein is not involved in urease activity but is essential for bacterial survival in vivo. *Infect. Immun.*, **66**, 4517–4521.
- Stingl, K., Brandt, S., Uhlemann, E.-M., Schmid, R., Altendorf, K., Zeilinger, C., Ecobichon, C., Labigne, A., Bakker, E.P. and de Reuse, H. (2007) Channel-mediated potassium uptake in *Helicobacter pylori* is essential for gastric colonization. *EMBO J.*, **26**, 232–241.
- Goodwin, A., Kersulyte, D., Sisson, G., Veldhuyzen van Zanten, S.J., Berg, D.E. and Hoffman, P.S. (1998) Metronidazole resistance in *Helicobacter pylori* is due to null mutations in a gene (*rdxA*) that encodes an oxygen-insensitive NADPH nitroreductase. *Mol. Microbiol.*, **28**, 383–393.
- Boneca, I.G., Ecobichon, C., Chaput, C., Mathieu, A., Guadagnini, S., Prévost, M.-C., Colland, F., Labigne, A. and de Reuse, H. (2008) Development of inducible systems to engineer conditional mutants of essential genes of *Helicobacter pylori*. *Appl. Environ. Microbiol.*, **74**, 2095–2102.
- Backert, S., Kwok, T. and König, W. (2005) Conjugative plasmid DNA transfer in *Helicobacter pylori* mediated by chromosomally encoded relaxase and TraG-like proteins. *Microbiol. Read. Engl.*, **151**, 3493–3503.
- Darfeuille, F., Unoson, C., Vogel, J. and Wagner, E.G.H. (2007) An antisense RNA inhibits translation by competing with standby ribosomes. *Mol. Cell*, **26**, 381–392.
- Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C. *et al.* (2012) Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. *Bioinformatics*, **28**, 1647–1649.
- Reuter, J.S. and Mathews, D.H. (2010) RNAstructure: software for RNA secondary structure prediction and analysis. *BMC Bioinformatics*, **11**, 129.

23. Bernacchi, S., Freisz, S., Maechling, C., Spiess, B., Marquet, R., Dumas, P. and Ennifar, E. (2007) Aminoglycoside binding to the HIV-1 RNA dimerization initiation site: thermodynamics and effect on the kissing-loop to duplex conversion. *Nucleic Acids Res.*, **35**, 7128–7139.
24. Fozo, E.M., Makarova, K.S., Shabalina, S.A., Yutin, N., Koonin, E.V. and Storz, G. (2010) Abundance of type I toxin-antitoxin systems in bacteria: searches for new candidates and discovery of novel families. *Nucleic Acids Res.*, **38**, 3743–3759.
25. Fischer, W., Breithaupt, U., Kern, B., Smith, S.I., Spicher, C. and Haas, R. (2014) A comprehensive analysis of *Helicobacter pylori* plasticity zones reveals that they are integrating conjugative elements with intermediate integration specificity. *BMC Genomics*, **15**, 310.
26. Kersulyte, D., Lee, W., Subramaniam, D., Anant, S., Herrera, P., Cabrera, L., Balqui, J., Barabas, O., Kalia, A., Gilman, R.H. *et al.* (2009) *Helicobacter Pylori*'s plasticity zones are novel transposable elements. *PLoS One*, **4**, e6859.
27. Durand, S., Jahn, N., Condon, C. and Brantl, S. (2012) Type I toxin-antitoxin systems in *Bacillus subtilis*. *RNA Biol.*, **9**, 1491–1497.
28. Jahn, N. and Brantl, S. (2013) One antitoxin—two functions: SR4 controls toxin mRNA decay and translation. *Nucleic Acids Res.*, **41**, 9870–9880.
29. Shokeen, S., Patel, S., Greenfield, T.J., Brinkman, C. and Weaver, K.E. (2008) Translational regulation by an intramolecular stem-loop is required for intermolecular RNA regulation of the par addiction module. *J. Bacteriol.*, **190**, 6076–6083.
30. Wen, J., Won, D. and Fozo, E.M. (2014) The ZorO-OrzO type I toxin-antitoxin locus: repression by the OrzO antitoxin. *Nucleic Acids Res.*, **42**, 1930–1946.
31. Möller-Jensen, J., Franch, T. and Gerdes, K. (2001) Temporal translational control by a metastable RNA structure. *J. Biol. Chem.*, **276**, 35707–35713.
32. Nagel, J.H., Gulyaev, A.P., Gerdes, K. and Pleij, C.W. (1999) Metastable structures and refolding kinetics in *hok* mRNA of plasmid R1. *RNA*, **5**, 1408–1418.
33. Xayaphoummine, A., Bucher, T. and Isambert, H. (2005) Kinefold web server for RNA/DNA folding path and structure prediction including pseudoknots and knots. *Nucleic Acids Res.*, **33**, W605–W610.
34. Thisted, T., Nielsen, A.K. and Gerdes, K. (1994) Mechanism of post-segregational killing: translation of *Hok*, *SrnB* and *Pnd* mRNAs of plasmids R1, F and R483 is activated by 3'-end processing. *EMBO J.*, **13**, 1950–1959.
35. Gerdes, K., Nielsen, A., Thorsted, P. and Wagner, E.G. (1992) Mechanism of killer gene activation. Antisense RNA-dependent RNase III cleavage ensures rapid turn-over of the stable *hok*, *srnB* and *pndA* effector messenger RNAs. *J. Mol. Biol.*, **226**, 637–649.
36. Durand, S., Gilet, L. and Condon, C. (2012) The essential function of *B. subtilis* RNase III is to silence foreign toxin genes. *PLoS Genet.*, **8**, e1003181.
37. Kawano, M. (2012) Divergently overlapping cis-encoded antisense RNA regulating toxin-antitoxin systems from *E. coli*: *hok/sok*, *ldr/rdl*, *symE/symR*. *RNA Biol.*, **9**, 1520–1527.
38. Thisted, T. and Gerdes, K. (1992) Mechanism of post-segregational killing by the *hok/sok* system of plasmid R1. *Sok* antisense RNA regulates *hok* gene expression indirectly through the overlapping *mok* gene. *J. Mol. Biol.*, **223**, 41–54.
39. Kawano, M., Oshima, T., Kasai, H. and Mori, H. (2002) Molecular characterization of long direct repeat (LDR) sequences expressing a stable mRNA encoding for a 35-amino-acid cell-killing peptide and a cis-encoded small antisense RNA in *Escherichia coli*. *Mol. Microbiol.*, **45**, 333–349.
40. Kawano, M., Aravind, L. and Storz, G. (2007) An antisense RNA controls synthesis of an SOS-induced toxin evolved from an antitoxin. *Mol. Microbiol.*, **64**, 738–754.
41. Pedersen, K. and Gerdes, K. (1999) Multiple *hok* genes on the chromosome of *Escherichia coli*. *Mol. Microbiol.*, **32**, 1090–1102.
42. Van Melderen, L. and Saavedra De Bast, M. (2009) Bacterial toxin-antitoxin systems: more than selfish entities? *PLoS Genet.*, **5**, e1000437.
43. Gerdes, K., Thisted, T. and Martinussen, J. (1990) Mechanism of post-segregational killing by the *hok/sok* system of plasmid R1: *sok* antisense RNA regulates formation of a *hok* mRNA species correlated with killing of plasmid-free cells. *Mol. Microbiol.*, **4**, 1807–1818.
44. Carraro, N., Poulin, D. and Burrus, V. (2015) Replication and active partition of integrative and conjugative elements (ICEs) of the SXT/R391 family: the line between ICEs and conjugative plasmids is getting thinner. *PLoS Genet.*, **11**, e1005298.
45. Wozniak, R.A.F. and Waldor, M.K. (2009) A toxin-antitoxin system promotes the maintenance of an integrative conjugative element. *PLoS Genet.*, **5**, e1000439.
46. Darty, K., Denise, A. and Ponty, Y. (2009) VARNA: interactive drawing and editing of the RNA secondary structure. *Bioinformatics*, **25**, 1974–1975.